天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> ACS Central Science >>article
ACS Central Science

ACS Central Science

IF: 12.69
Download PDF

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.

Published:1 April 2021 DOI: 10.1001/jamanetworkopen.2021.5250 PMID: 33835174
De-Shen Wang, Ming-Tao Hu, Zhi-Qiang Wang, Chao Ren, Miao-Zhen Qiu, Hui-Yan Luo, Ying Jin, William Pat Fong, Shu-Bin Wang, Jie-Wen Peng, Qing-Feng Zou, Qiong Tan, Feng-Hua Wang, Yu-Hong Li

Abstract

Importance: The prevention of chemotherapy-induced nausea and vomiting has an important role in the overall management of cancer treatment.

Objective: To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk.

Design, setting, and participants: This phase 3, double-blind, placebo-controlled randomized clinical trial recruited young women (age ≤50 years) who drank little or no alcohol and had gastrointestinal cancer for which they received FOLFOX or FOLFIRI chemotherapy. A total of 248 women were enrolled and assigned in the ratio 1:1 to intervention and control groups from August 4, 2015, to March 31, 2020. Intention-to-treat analysis was used to evaluate patient baseline characteristics and efficacy. The analysis was conducted on October 30, 2020.

Interventions: Patients were randomly assigned to the aprepitant group (aprepitant, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 6 mg, orally 30 minutes before chemotherapy initiation on day 1) or the placebo group (placebo, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally on each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 12 mg, orally 30 minutes before chemotherapy initiation on day 1).

Main outcomes and measures: The primary end point was the complete response (CR) rate, defined as the proportion of patients without emesis episodes or rescue medication use during the overall phase of the first cycle. Other efficacy indicators, such as no vomiting and no nausea, were measured as the secondary and exploratory end points.

Results: A total of 248 women from 4 clinical centers in China entered this study, and 243 patients (aprepitant regimen, 125 patients [51.4%]; placebo regimen, 118 patients [48.5%]) were evaluable for efficacy and safety; mean (SD) age of the total population was 40.1 (7.3) years. The CR rate was significantly higher in the aprepitant group vs the control group overall (107 [87.0%] vs 80 [66.7%]; P?

Conclusions and relevance: The combination of aprepitant with palonosetron and dexamethasone provided increased antiemetic efficacy in the FOLFOX or FOLFIRI chemotherapy regimen and was well tolerated by younger women with gastrointestinal cancer who have a history of little or no alcohol consumption.

Trial registration: ClinicalTrials.gov Identifier: NCT03674294.

Substances (10)

Related products
Procduct Name CAS Molecular Formula Supplier Price
5-Fluorouracil 51-21-8 C4H3FN2O2 941 suppliers $5.00-$2492.67
Dexamethasone 50-02-2 C22H29FO5 783 suppliers $20.00-$5210.50
Aprepitant 170729-80-3 C23H21F7N4O3 619 suppliers $5.00-$3204.00
Irinotecan 97682-44-5 C33H38N4O6 416 suppliers $29.00-$1400.00
Oxaliplatin 63121-00-6 C8H12N2O4Pt 169 suppliers Inquiry
Folinic acid 58-05-9 C20H23N7O7 143 suppliers Inquiry
Palonosetron 135729-61-2 C19H24N2O 67 suppliers $42.00-$1212.75
FOLFIRI 1000669-05-5 C57H64FN13O15 1 suppliers Inquiry
PLACEBO FOR DUR-928 TOPICAL SOLUTION 1 suppliers Inquiry
Folfox protocol - Inquiry

Similar articles

IF:1.6

Effect of zinc sulfate supplementation on premenstrual syndrome and health-related quality of life: Clinical randomized controlled trial

Journal of Obstetrics and Gynaecology Research Shiva Siahbazi, Samira Behboudi-Gandevani,etc Published: 11 February 2017